Sciele Pharma, Inc., a Shionogi Company, today announced the availability of Ulesfia (Benzyl Alcohol Lotion 5%), the first and only prescription medication that kills head lice by asphyxiation without potential neurotoxic side effects. Approved by the U.S. Food & Drug Administration (FDA), Ulesfia is available now by prescription nationwide in time for peak head lice season as children will shortly be headed back to school.
Each year, approximately 6 to 12 million children between the ages of 3 and 12 years are infested with head lice, parasites that survive by injecting small amounts of saliva and removing small amounts of blood from the scalp every few hours. To survive, lice breathe through sophisticated breathing holes that close upon contact with most liquids, allowing the lice to go into suspended animation and survive for hours without respiration. Ulesfia's unique mechanism of action is facilitated through the use of benzyl alcohol which prevents lice from closing their breathing holes, thereby asphyxiating them and causing death. Ulesfia is an effective head lice treatment that does not contain harsh chemicals and addresses the increasing resistance of lice to therapies that contain neurotoxic chemicals.
Full prescribing information for Ulesfia (Benzyl Alcohol Lotion 5%) is available at www.sciele.com.
NEWS: Unique Product Asphyxiates Head Lice, Can Help With Outbreaks as Children Head Back to School
FORMAT: B-roll and Soundbites
ADDITIONAL RESOURCES: Video, contact information and more available at: http://www.prnewswire.com/broadcast/37282/consumer.html
VIDEO PROVIDED BY: Sciele Pharma, Inc., a Shionogi Company
Contact: FOR MORE INFORMATION, PLEASE CALL: MultiVu Media Relations, 1-800-653-5313 EXT. 3
SOURCE Sciele Pharma, Inc., a Shionogi Company
CONTACT: FOR TECHNICAL INFORMATION OR HARD COPY, PLEASE CALL: MultiVu
Media Relations, 1-800-653-5313 EXT. 3
Web site: http://www.sciele.com/